Asian Spectator

Men's Weekly

.

Twelve Rising Talents from Germany Complete Five-Day Visit to Hong Kong and Shenzhen Experiencing the Region’s Vibrant Innovation and Technology Ecosystem

The visit showcased Hong Kong’s appeal as a launchpad for global talent and startups to the winners of a pitch competition hosted by Hong Kong Talent Engage in partnership with Germany's Young F...

COVID-19 Pandemic Brought Under Control in China with Favipira...

BEIJING, China, June 27, 2020, Antara COVID-19 has become a global pandemic. China’s successful control of the pandemic has set a good example for other countries. Many have followed C...

PlayUp grows Texas presence with Panther City Lacrosse Club pa...

LAS VEGAS, Nev., Feb. 9, 2022 /PRNewswire-AsiaNet/ -- Agreement marks operators foray into Lone Star StatePlayUp today announced a groundbreaking agreement with the Panther City Lacrosse Clu...

Kerry Logistics Extends into Coffee Trading and Distribution of Full illycaffe Product Range with Establishment of Kerry Coffee

Robert Berger, Executive Director - Fashion & Lifestyle of Kerry Logistics (Hong Kong), oversees Kerry Coffee, which consolidates illycaffe's entire product selection under a sole distri...

Xinhua Silk Road: Seraphim, Resolar sign MoU to deepen coopera...

BEIJING, July 21, 2022 /PRNewswire-Asianet/ -- Seraphim Energy Group Co., Ltd. (Seraphim), a leading global solar product manufacturer, signed a memorandum of understanding (MoU) with Resola...

Easy-drying.Anti-bacterial.Skin-friendly Comfortable and Refreshing Sleep Experience Casablanca Proudly Introduces CuDry+ New Functional Fiber Bedding Series

HONG KONG SAR - Media OutReach Newswire - 31 May 2024 - In recent years, extreme weather conditions have been occurring frequently, including heatwaves, heavy rainfalls, and in March of thi...

Semaglutide 2.4 mg injection demonstrated significant weight l...

BAGSVÆRD, Denmark, Nov. 5, 2020 /PRNewswire-AsiaNet / -- Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to inten...

Philippine fintech leader GCash joins plenary at Mobile World Congress

MANILA, PHILIPPINES - Media OutReach - 23 February 2023 - The Philippines #1 Fintech App GCash, operated by the Globe Group's Mynt, will join the plenary of the Mobile World Congress in B...

Mother's Day: Xi Inspired by His Mother in Shaping Outlook on ...

BEIJING, May 10, 2021 /PRNewswire-AsiaNet/ -- For Chinese President Xi Jinping, "family is people's first classroom, and parents are children's first teachers." The indelible words from his ...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Krisis legitimasi pejabat negara: Terpilih dalam pemilu, tapi gagal jaga kepercayaan rakyat

Pengendara motor melintasi alat kampanye untuk calon anggota legislatif nasional dan daerah jelang Pemilu 2024 di Bintaro, Tangerang Selatan, pada 29 Desember 2023.Gilangpnp/Shutterstock● Masyar...

Belajar dari pasangan Jawa dan Tionghoa: Strategi negosiasi untuk hubungan antar etnis

Pernikahan Antar Etnis antara Jawa dan TionghoaLipik Stock Media/Shuttershock● Pernikahan beda suku tak selalu kental dengan konflik antar etnis.● Pernikahan antar etnis justru menghasilka...

Diplomasi FOMO Prabowo: Simbolis, reaktif, berisiko mengancam legitimasi

Presiden Prabowo Subianto menghadiri BRICS Leaders Virtual Meeting dari kediaman pribadinya di Kertanegara, Jakarta Selatan, pada Senin, 8 September 2025.Cahyo/Biro Pers Sekretariat Presiden, CC BY ...